Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00537446 · ClinicalTrials.gov registry record · NA
Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis
A NA study, sponsored by Columbia University.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT00537446 is a NA study that was terminated before completion, run by Columbia University. The registered enrollment target is 8 participants.
The verdict
NCT00537446, a NA study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
Amyotrophic Lateral Sclerosis (ALS), or "Lou Gehrig's Disease", is a fatal disorder that causes progressive degeneration and weakening of the muscles of breathing, leading to breathing insufficiency and eventually breathing failure. This breathing insufficiency is commonly treated with a breathing assistance device, known as noninvasive positive pressure ventilation (NIPPV). While generally well tolerated and accepted, it is not clear whether or to what extent NIPPV in fact helps breathing function: some data suggest that NIPPV preserves breathing function over time, whereas other data suggest that it actually causes breathing function to decline more quickly. No studies have shown what the acute effect of NIPPV is on breathing muscle function in ALS patients. This study will test the hypothesis that the acute use of NIPPV, at pressure levels that are in common clinical use, will cause measurable changes in tests of breathing function, compared to baseline and to lower levels of NIPPV. We expect that the results of this study will help to clarify whether and to what extent NIPPV assists respiratory muscle function in patients with ALS.
Interventions
- DEVICE noninvasive positive pressure ventilation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-09 |
| Est. Completion | 2012-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00537446
The ClinicalTrials.gov registry entry for NCT00537446 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which noninvasive positive pressure ventilation is the first listed.
NCT00537446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00537446 about?
NCT00537446 is a clinical study titled "Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis". Amyotrophic Lateral Sclerosis (ALS), or "Lou Gehrig's Disease", is a fatal disorder that causes progressive degeneration and weakening of the muscles of breathing, leading to breathing insufficiency and eventually breathing failure. This breathing insufficiency is commonly treated with a breathing a...
What is the current status of trial NCT00537446?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2007-09. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00537446?
The interventions under investigation include: noninvasive positive pressure ventilation (DEVICE).
Who is sponsoring clinical trial NCT00537446?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.